Press Release: PledPharma : First Asian patient has been included in the global Phase III program for PledOx® and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharma

PledPharma AB (publ) and Solasia Pharma K.K. announces that the first patient has been included in the global Phase III program for the drug candidate PledOx® in Japan. This constitutes an important milestone for both companies. The inclusion will trigger a payment from PledPharma's partner Solasia Pharma of 600 MJPY, equivalent to approximately 49 MSEK.